MedDataX Logo

Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol

NCT ID: NCT00454831

Last Updated: 2007-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

207 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect.

This study was designed to determine if HEP-40 chitosan (Enzymatic Polychitosamine Hydrolysate - 40kDa), a short-chained chitosan with a molecular weight of 40 kDa, is safe and effective in lowering LDL-cholesterol levels in patients with mild to moderately elevated cholesterol levels and who have not been previously treated with other lipid-lowering agents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chitosan is a natural product that is produced commercially through the deacetylation of chitin, which is found in the exoskeleton of crustaceans. It has been suggested that chitosan has a lipid-lowering effect by binding to fatty acids and cholesterol in the gastrointestinal tract and restricting their absorption.

This study was designed to determine if HEP-40 chitosan (Enzymatic Polychitosamine Hydrolysate - 40kDa), a short-chained chitosan with a molecular weight of 40 kDa, is safe and effective in lowering LDL-cholesterol levels in patients who have not been previously treated with lipid-lowering agents and who have cholesterol levels that are mild to moderately above the levels recommended by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

This is a multi-centre, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase where patients will be instructed to maintain a stable diet, patients will be randomized to one of the following study groups for a 12-week Active Treatment Phase:

* HEP-40 400 mg three times a day (400 mg TID)
* HEP-40 800 mg twice a day (800 mg BID)
* HEP-40 800 mg three times a day (800 mg TID)
* HEP-40 2400 mg once a day (2400 mg QD)
* Placebo, three times a day (placebo)

The primary objective is to evaluate the clinical benefit of administering HEP-40 chitosan at different doses and at different dosing regimens compared with placebo. Clinical benefit will be defined as the reduction in LDL-cholesterol after 4 weeks of active treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypercholesterolemia LDL-cholesterol chitosan HEP-40

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HEP 400mg TID

HEP-40 400 mg three times a day

Group Type ACTIVE_COMPARATOR

HEP-40 chitosan

Intervention Type DEVICE

Enzymatically Hydrolyzed Polychitosamine-40 kDa

HEP 800mg BID

HEP-40 800 mg twice a day

Group Type ACTIVE_COMPARATOR

HEP-40 chitosan

Intervention Type DEVICE

Enzymatically Hydrolyzed Polychitosamine-40 kDa

HEP 800mg TID

HEP-40 800 mg three times a day

Group Type ACTIVE_COMPARATOR

HEP-40 chitosan

Intervention Type DEVICE

Enzymatically Hydrolyzed Polychitosamine-40 kDa

HEP 2400mg QD

HEP-40 2400 mg once a day

Group Type ACTIVE_COMPARATOR

HEP-40 chitosan

Intervention Type DEVICE

Enzymatically Hydrolyzed Polychitosamine-40 kDa

Placebo

Placebo, three times a day

Group Type PLACEBO_COMPARATOR

HEP-40 chitosan

Intervention Type DEVICE

Enzymatically Hydrolyzed Polychitosamine-40 kDa

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HEP-40 chitosan

Enzymatically Hydrolyzed Polychitosamine-40 kDa

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Libracol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with borderline, mild or moderate hypercholesterolemia, defined as LDL-C levels between 2.0 mmol/L and 4.5 mmol/L;
* At low (≤10%) or moderate (11-19%) 10-year risk for cardiovascular disease according to the Framingham model;
* Treatment-naïve for any lipid-lowering medications including statins, other pharmaceuticals or nutraceuticals;
* Stable diet and willing to continue on the dietary regimen recommended by their physician (NCEP Step 1 Diet) for the duration of the study;
* Woman of child bearing potential must be practicing effective birth control for a period of at least one month prior to initiation of the study.

Exclusion Criteria

* Any concomitant condition which in the opinion of the investigator would preclude the patient from successfully participating in the study;
* Pregnant or that are breast feeding;
* Participation in another clinical trial within 30 days from initiation of the study;
* Known cardiac disease including: congestive heart failure, cardiac arrhythmias, unstable angina, myocardial infarction within the last 6 months, or uncontrolled malignant hypertension;
* High risk of developing coronary artery disease;
* Any condition affecting a major organ system, such as liver or kidney disease or malignancy;
* Uncontrolled diabetes mellitus or newly diagnosed patients (within 3 months) or recent change in anti-diabetic pharmacotherapy within 3 months of screening;
* Evidence of active renal disease indicated by serum creatinine \> 2.0 mg/dL;
* Known HIV or Hepatitis B or C positive;
* Concurrent use of corticosteroids;
* Allergy or intolerance to crustaceans and/or seafood products.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

JSS Medical Research Inc.

INDUSTRY

Sponsor Role collaborator

DNP Canada

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacques HF Lenis, MD

Role: PRINCIPAL_INVESTIGATOR

Recherche Invascor Inc

John S Sampalis, PhD

Role: STUDY_DIRECTOR

JSS Medical Research Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

JSS Medical Research Inc.

Westmount, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

153-PTL-001

Identifier Type: -

Identifier Source: org_study_id